# ALN-APOC3 in Adult Participants With Dyslipidemia

> **NCT06784349** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** ALN-APOC3
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT06784349
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-27
- **Primary completion:** 2026-02-25
- **Final completion:** 2026-02-25
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784349, "ALN-APOC3 in Adult Participants With Dyslipidemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06784349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*